Featured Research

from universities, journals, and other organizations

Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding and death, researchers report

Date:
February 3, 2012
Source:
American Heart Association
Summary:
The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke, according to new research.

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments will continue. The SPS3 trial is the first large-scale study of patients with subcortical strokes, which occur when small blood vessels deep in the middle of the brain are blocked, damaging small areas of brain tissue. This type of stroke affects about 150,000 Americans each year, and is the most common cause of vascular dementia according to Oscar Benavente, M.D., lead author of the study and a professor of neurology at Canada's University of British Columbia in Vancouver, British Columbia.

American Heart Association/American Stroke Association guidelines for preventing recurrent strokes recommend anti-clotting medications like aspirin, the customary treatment, or other clot preventives like clopidogrel, but not the combination of aspirin plus clopidogrel.

Treatments have not been compared in patients with subcortical strokes specifically.

In the United States, stroke is the No. 4 killer and a leading cause of disability among adults.

Beginning in March 2003, the SPS3 study included 3,020 patients at 81 sites in the United States, Canada, Spain, Mexico and South America. Stroke patients were randomly assigned within 180 days of symptom onset to receive aspirin and clopidogrel or aspirin plus placebo daily. Neither researchers nor patients knew who received placebo or the study drug.

Preliminary findings showed that the risk of bleeding nearly doubled among patients on the clopidogrel/aspirin combination, compared to those on aspirin and placebo: Aspirin plus placebo had a 1.1 percent of bleeding risk per year and aspirin plus clopidogrel a 2.1 percent bleeding risk per year -- largely from major bleeds somewhere other than in the brain.

Similarly, the annual risk of death was greater with the combined therapy: Aspirin plus placebo had a 1.4 percent risk of death and aspirin plus clopidogrel had a 2.1 percent risk of death.

There was no difference in stroke recurrence in both treatment arms.

"These interim results do not support the use of combination clopidogrel plus aspirin for secondary stroke prevention in patients with small subcortical strokes," the researchers said.

Co-investigator is Robert G. Hart, M.D.

The National Institutes of Health, National Institute of Neurological Diseases and Stroke, funded the study.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding and death, researchers report." ScienceDaily. ScienceDaily, 3 February 2012. <www.sciencedaily.com/releases/2012/02/120203113319.htm>.
American Heart Association. (2012, February 3). Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding and death, researchers report. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/02/120203113319.htm
American Heart Association. "Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding and death, researchers report." ScienceDaily. www.sciencedaily.com/releases/2012/02/120203113319.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins